Lipid Transport Disorder Italian Genetic Record (LIPIGEN)
NCT06362473 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2024-04-12
Summary
LIPIGEN is an observational study involving Italian physicians and researchers in the field of diseases related to blood lipid levels. This study aims to improve the diagnosis and treatment of people with familial dyslipidaemias, including very common conditions such as familial hypercholesterolaemia (FH) and less common ones such as familial chylomicronidaemic syndrome (FCS).
What does the study do?
It collects information on Italian patients with Familial Hypercholesterolaemia (FH), following them in their normal clinical examination without adding extra procedures.
It uses the data collected to further our understanding of diseases such as familial hypercholesterolaemia, examining how it is diagnosed clinically and by genetic testing, and evaluating the effectiveness of different treatments.
It seeks to identify the genetic mutations that cause familial hypercholesterolaemia and other dyslipidaemias, helping to choose the most effective treatments.
It evaluates the impact of long-term treatments and patient adherence to medication, as well as monitoring the incidence of cardiovascular events and other important outcomes.
Who can participate?
The study is aimed at people of all ages, from children to adults, with familial hypercholesterolaemia or other genetic dyslipidaemia.
More than 50 centres throughout Italy are involved, making the study accessible to many.
What does participation entail?
Participants will continue with their normal clinical practice.
Data such as family history, personal clinical findings and genetic information will be collected, without additional procedures.
For some, further evaluations, such as ultrasounds, may be required to better study their condition.
The LIPIGEN study not only helps to better understand diseases related to high cholesterol but also aims to improve patients\' lives through more precise diagnosis and personalised treatments.
Conditions
- Familial Hypercholesterolemia
- Genetic Disorder
Interventions
- DRUG
-
Lipid-lowering treatments
Sponsors & Collaborators
-
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
lead OTHER
Principal Investigators
-
Alberico L Catapano, PhD · Fondazione S.I.S.A.
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-08-04
- Primary Completion
- 2026-09-30
- Completion
- 2026-09-30
Countries
- Italy
Study Locations
More Related Trials
-
Treatment of Hyperlipidemia and Sexual Dysfunction
NCT00923676 ·Status: UNKNOWN ·Phase: PHASE4
-
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
NCT00169559 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
NCT04485793 ·Status: COMPLETED ·Phase: NA
-
Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia
NCT01266876 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy
NCT04141475 ·Status: TERMINATED ·Phase: NA
-
HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism
NCT02354079 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy
NCT06287177 ·Status: RECRUITING
-
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
NCT05610280 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)
NCT01436253 ·Status: COMPLETED
-
Effects of Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve
NCT02969070 ·Status: COMPLETED ·Phase: NA
-
The Role of a Combination of Nutraceuticals in the Control of Cardiovascular Risk
NCT01293162 ·Status: COMPLETED
-
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
NCT00304993 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia
NCT01239992 ·Status: TERMINATED ·Phase: PHASE4
-
Medical Students' Evaluation of Dyslipidemia and LIPoprotein(a) Study
NCT06482476 ·Status: RECRUITING
-
Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides
NCT02585869 ·Status: COMPLETED ·Phase: PHASE2
-
Extreme Lipids Repository
NCT04156997 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol
NCT01122355 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia
NCT01211847 ·Status: COMPLETED ·Phase: PHASE2
-
Nutraceuticals to Improve Lipid Profile in European Countries
NCT01649986 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol
NCT00927459 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
NCT05552326 ·Status: COMPLETED ·Phase: PHASE3
-
Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment
NCT02153879 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Lipid Regulating Effects of TRIA-662
NCT00758303 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
NCT01618916 ·Status: COMPLETED ·Phase: PHASE1
-
the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C
NCT06132360 ·Status: COMPLETED ·Phase: PHASE1